DISEASE SCANNER
Global Incurable Diseases Tracker
Gastric (Stomach) Cancer
Adenocarcinoma of the stomach, often associated with H. pylori infection, smoking, diet (salted/preserved foods), and genetic factors. Incidence declining in West but remains high in East Asia. Lauren classification: intestinal and diffuse types.
1.1M
15
Symptoms
Treatment Options
Risk Factors
Diagnostic Methods
- 1Biopsy
- 2Imaging (CT, MRI, PET)
- 3Tumor markers
- 4Genetic testing
- 5Endoscopy
- 6Blood tests
- 7Screening programs
Prognosis
Improved with early detection. Stage I: 5-year survival 70-90%. Stage II: 5-year survival 50-60%. Stage III: 5-year survival 20-40%. Stage IV (metastatic): 5-year survival 5-10%. Overall 5-year survival approximately 32%. Curative potential with complete surgical resection. Chemotherapy and radiation improve outcomes. HER2-positive tumors respond to trastuzumab. MSI-high tumors respond to immunotherapy. Quality of life maintained with palliative care in advanced disease.
Prevention
- Smoking cessation
- Sun protection
- Healthy diet
- Regular exercise
- Vaccination (HPV, HBV)
- Screening programs
- Limit alcohol
- Maintain healthy weight
Research Status
HER2-targeted therapy (trastuzumab) for HER2+ disease. CLDN18.2-targeted therapy (zolbetuximab) approved. Immunotherapy (nivolumab, pembrolizumab) in combination. MSI-H tumors respond well to immunotherapy.
Affected Countries
Sources
- https://www.cancer.gov
- https://www.who.int/cancer
- https://www.cancer.org
Medical Disclaimer
This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.